scholarly journals Glycerolipids of alkyl type - modulators of tumoral cells destruction

2010 ◽  
Vol 56 (4) ◽  
pp. 457-470 ◽  
Author(s):  
S.G. Romanova ◽  
V.G. Romanov ◽  
G.A. Serebrennikova ◽  
A.A. Shtil

The review is summarizes current information on biological activity and search of the antineoplastic mechanism of action of alkyl glycerolipids. Special attention is paid to following problems: selective ability phosphorus alkyl glycerolipids, antineoplastic activity, cytostatic and cytotoxic effects of edelfosine and its analogues. The review contains set of the data known for today from the literature, on the possible mechanism cytoyoxic actions of such connections.

2021 ◽  
Vol 22 ◽  
Author(s):  
Zhang Jing ◽  
Wang Rui ◽  
Li Ruihua ◽  
Yu Hao ◽  
Fang Hengtong

: Since the discovery of (2α,3β)-2,3-dihydroxyolean-12-en-28-oic acid, also known as maslinic acid, many studies have examined its biological activity, which has been shown to promote health and resist various diseases. This article focuses on previous research on maslinic acid and mainly reviews its reported effects on cardiovascular diseases, neuroprotection, diabetes, cancer, inflammation, and pathogens. Maslinic acid exerts positive effects on both cell and animal models of disease. Although its mechanism of action has not yet been completely elucidated, maslinic acid is feasible as a nutritional additive and has the potential to be developed as a drug.


Endocrinology ◽  
2003 ◽  
Vol 144 (5) ◽  
pp. 1671-1674 ◽  
Author(s):  
Alan Schneyer ◽  
Amy Schoen ◽  
Alicia Quigg ◽  
Yisrael Sidis

Modulation of activin and other TGFβ superfamily signaling is the primary mechanism of action for both follistatin (FS) and FS-like 3 (FSTL-3). However, most studies of these ligands use activin A due to its wide availability. We have now tested the ability of FS288 and FSTL-3 to bind and neutralize activin B relative to activin A. Activin B bound to both FS and FSTL-3 at a potency approximately 10-fold lower than that of activin A. Moreover, whereas both activins had similar biological activity in 293 cell reporter assays, FS and FSTL-3 were approximately 3-fold more effective in neutralizing activin A relative to activin B. These results suggest that neutralization of activins A and B by FS and FSTL-3 are not identical, so that the relative activity of each activin in tissues where both are produced, such as in the ovary, could be quite different. In addition, biological systems that use primarily activin B, but which have been examined in vitro using activin A, may need to be reevaluated to determine the actual physiologic roles of FS or FSTL-3.


2014 ◽  
Vol 38 (3) ◽  
pp. 377-382 ◽  
Author(s):  
Monika Z. Kaczmarek ◽  
Ryan J. Holland ◽  
Stephen A. Lavanier ◽  
Jami A. Troxler ◽  
Valentyna I. Fesenkova ◽  
...  

2010 ◽  
Vol 159 (4) ◽  
pp. 909-918 ◽  
Author(s):  
Sheng Xiong ◽  
Hui-dan Pang ◽  
Jun Fan ◽  
Feng Ge ◽  
Xiao-xia Yang ◽  
...  

2014 ◽  
Vol 48 (4) ◽  
pp. 235-237 ◽  
Author(s):  
M. Kh. Salimgareeva ◽  
E. I. Farafontova ◽  
G. S. Abdrakhimova ◽  
S. P. Ivanov ◽  
Yu. V. Vakhitova

2017 ◽  
Vol 57 (3) ◽  
Author(s):  
Ignacio E. León ◽  
Susana B. Etcheverry ◽  
Beatriz S. Parajón-Costa ◽  
Enrique J. Baran

The oxovanadium(IV) complex of oxodiacetic acid (H<sub>2</sub>ODA) and 2,2’-bipyridine (bipy) of stoichiometry [VO(ODA)(bipy)]⋅H<sub>2</sub>O, was thoroughly characterized by infrared, Raman and electronic spectroscopies. The biological activity of the complex on the cell proliferation was tested on osteoblast-like cells (MC3T3E1 osteoblastic mouse calvaria-derived cells and UMR106 rat osteosarcoma-derived cells) in culture. The complex caused inhibition of cellular proliferation in both osteoblast-like cells in culture, but its action was statistically stronger in the tumoral cells. This effect was specially marked with increasing concentrations of the complex. Based on these preliminary biological results, [VO(ODA)(bipy)]⋅H<sub>2</sub>O can be considered as a good candidate to be further investigated in relation to cancer treatment.


2019 ◽  
Vol 184 ◽  
pp. 111742 ◽  
Author(s):  
Elaine Soares Coimbra ◽  
Marcus Vinícius Nora de Souza ◽  
Mariana Sequetto Terror ◽  
Alessandra Campbell Pinheiro ◽  
Juliana da Trindade Granato

Sign in / Sign up

Export Citation Format

Share Document